Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 16, 2013

Quest Acquires Concentra’s Toxicology, Clinical Lab Business

  • Quest Diagnostics today said it has acquired the toxicology and clinical laboratory business of Humana subsidiary Concentra. Further, Quest has agreed to be Concentra’s primary provider of workplace drug toxicology and clinical lab testing. Financial terms were not disclosed.

    "With this transaction, Concentra's patients, physicians, and employer clients will gain access to Quest's industry-leading menu of innovative workplace drug and clinical lab diagnostic information services," Steve Rusckowski, Quest president and CEO, said in a statement.

    Under the terms of the agreements, Quest has acquired the assets of Concentra's Memphis, TN-based Advanced Toxicology Network (ATN) lab business, and will provide Concentra and its employer clients and clinical laboratory testing services to patients and physicians in Concentra's network of primary care and urgent care facilities.

    Quest added that the ATN business will be transitioned into its national lab network by the end of this year.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »